Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

    Summary
    EudraCT number
    2020-002213-18
    Trial protocol
    FR   DE   BE   PL   GR   IT  
    Global end of trial date
    29 Jun 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    22 Aug 2024
    First version publication date
    22 Aug 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    EDP 938-103
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04633187
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    IND: 135874
    Sponsors
    Sponsor organisation name
    Enanta Pharmaceuticals, Inc.
    Sponsor organisation address
    500 Arsenal St., Watertown, United States, MA 02472
    Public contact
    Medical Monitor, Enanta Pharmaceuticals, Inc., +1 617607 0705, nadda@enanta.com
    Scientific contact
    Medical Monitor, Enanta Pharmaceuticals, Inc., +1 617607 0705, nadda@enanta.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    08 May 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    29 Jun 2023
    Global end of trial reached?
    Yes
    Global end of trial date
    29 Jun 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the effect of EDP-938 on the development of lower respiratory tract complication (LRTC) in hematopoietic cell transplant (HCT) participants with an acute respiratory syncytial virus (RSV) infection of the upper respiratory tract (URTI)
    Protection of trial subjects
    The study was conducted in compliance with this protocol, the principles of E6 Good Clinical Practice: Consolidated Guidance (ICH-GCP), the Declaration of Helsinki, and all applicable local laws and regulations governing clinical studies. Each participant provided a signed and dated ICF before enrollment into the study.
    Background therapy
    The most frequently reported concomitant medication drug class in the EDP-938 treatment group (>40% of participants) were antibacterials for systemic use, antivirals for systemic use, drugs for acid related disorders (5 participants [100%] each), immunosuppressants, analgesics, antianemic preparations (4 participants [80%] each), corticosteroids for systemic use and antimycotics for systemic use (3 participants [60%] each).
    Evidence for comparator
    This study is placebo-controlled and placebo is used for comparator.
    Actual start date of recruitment
    01 Nov 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Spain: 3
    Country: Number of subjects enrolled
    Belgium: 1
    Country: Number of subjects enrolled
    Italy: 1
    Country: Number of subjects enrolled
    Brazil: 1
    Country: Number of subjects enrolled
    Israel: 1
    Country: Number of subjects enrolled
    South Africa: 1
    Country: Number of subjects enrolled
    Türkiye: 1
    Worldwide total number of subjects
    9
    EEA total number of subjects
    5
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    9
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    A total of 9 participants were randomly assigned to receive either EDP-938 or Placebo. 5 participants were randomized to the EDP-938 treatment group (1 to 150 mg, 1 to 400 mg, and 3 to 800 mg EDP-938) and 4 participants were randomized to the placebo treatment group. All randomized participants completed the treatment and follow-up.

    Pre-assignment
    Screening details
    190 participants were planned to be randomized. However, due to low enrollment, the study was terminated after 9 participants were randomized and completed treatment.

    Pre-assignment period milestones
    Number of subjects started
    9
    Number of subjects completed
    9

    Period 1
    Period 1 title
    Treatment Period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    EDP-938
    Arm description
    Participants were randomly assigned (2:1 ratio) on Day 1 to receive EDP-938 administered orally once daily (QD) for a total of 21 days.
    Arm type
    Experimental

    Investigational medicinal product name
    EDP-938
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants were randomly assigned (2:1 ratio) on Day 1 to receive EDP-938 administered orally once daily (QD) for a total of 21 days. The dose administered QD was to be either: - 800 mg of EDP-938 (for participants not taking azole antifungals that were moderate or strong CYP3A4 inhibitors) - 400 mg of EDP-938 (for participants taking azole antifungals that were moderate CYP3A4 inhibitors) - 150 mg of EDP-938 (for participants taking azole antifungals that were strong CYP3A4 inhibitors)

    Arm title
    Placebo
    Arm description
    Participants were randomly assigned (2:1 ratio) on Day 1 to receive Placebo administered orally once daily (QD) for a total of 21 days.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants were randomly assigned (2:1 ratio) on Day 1 to receive Placebo administered orally once daily (QD) for a total of 21 days. The dose administered QD was to be either: - 800 mg of Placebo (for participants not taking azole antifungals that were moderate or strong CYP3A4 inhibitors) - 400 mg of Placebo (for participants taking azole antifungals that were moderate CYP3A4 inhibitors) - 150 mg of Placebo (for participants taking azole antifungals that were strong CYP3A4 inhibitors)

    Number of subjects in period 1
    EDP-938 Placebo
    Started
    5
    4
    Completed
    5
    4

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    EDP-938
    Reporting group description
    Participants were randomly assigned (2:1 ratio) on Day 1 to receive EDP-938 administered orally once daily (QD) for a total of 21 days.

    Reporting group title
    Placebo
    Reporting group description
    Participants were randomly assigned (2:1 ratio) on Day 1 to receive Placebo administered orally once daily (QD) for a total of 21 days.

    Reporting group values
    EDP-938 Placebo Total
    Number of subjects
    5 4 9
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    5 4 9
        From 65-84 years
    0 0 0
        85 years and over
    0 0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    44.4 ( 15.98 ) 44.3 ( 15.99 ) -
    Gender categorical
    Units: Subjects
        Female
    2 2 4
        Male
    3 2 5

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    EDP-938
    Reporting group description
    Participants were randomly assigned (2:1 ratio) on Day 1 to receive EDP-938 administered orally once daily (QD) for a total of 21 days.

    Reporting group title
    Placebo
    Reporting group description
    Participants were randomly assigned (2:1 ratio) on Day 1 to receive Placebo administered orally once daily (QD) for a total of 21 days.

    Subject analysis set title
    ITT population
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    The Intent-to-Treat (ITT) population included all participants who received at least one dose of study drug. All participants in the ITT population were analyzed according to the treatment as randomized. The ITT population was used for the primary efficacy analysis and analysis of FLU-PRO data.

    Subject analysis set title
    mITT by RT-qPCR population
    Subject analysis set type
    Modified intention-to-treat
    Subject analysis set description
    The modified Intent-to-Treat by RT-qPCR (quantitative reverse transcription polymerase chain reaction) (mITT by RT-qPCR) population included all participants in the ITT population, excluding participants who had undetectable or missing RSV viral load by RT-qPCR at baseline. The mITT by RT-qPCR population was used for efficacy analysis of RSV viral load by RT-qPCR.

    Subject analysis set title
    mITT by CBIA
    Subject analysis set type
    Modified intention-to-treat
    Subject analysis set description
    The modified Intent-to-Treat by cell-based infectivity assay (CBIA) (mITT by CBIA) population included all participants in the ITT population, excluding participants who had undetectable or missing RSV viral load by CBIA at baseline. The mITT by CBIA population was used for efficacy analysis of RSV viral load by CBIA.

    Subject analysis set title
    SAF Population
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    The Safety (SAF) Population included all participants who received at least one dose of study drug. All participants in the safety population were analyzed according to the treatment actually received.

    Primary: Incidence of LRTC through Day 28 defined as determined by the Endpoint Adjudication Committee

    Close Top of page
    End point title
    Incidence of LRTC through Day 28 defined as determined by the Endpoint Adjudication Committee [1]
    End point description
    For the primary efficacy endpoint, the incidence of LRTC as determined by the Endpoint Adjudication Committee was 0% (0 of 5 participants) in the EDP-938-treatment group and 25% (1 of 4 participants) in the placebo treatment group. The single LRTC reported in the placebo group was categorized as an LRTC due to unknown etiology by the Endpoint Adjudication Committee.
    End point type
    Primary
    End point timeframe
    Through Day 28
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were performed.
    End point values
    EDP-938 Placebo
    Number of subjects analysed
    5
    4
    Units: percent
    number (not applicable)
        Incidence of LRTC as determined by the Endpoint Ad
    0
    25
    No statistical analyses for this end point

    Secondary: RSV Viral Load by RT-qPCR AUC From Day 1 Through Day 49

    Close Top of page
    End point title
    RSV Viral Load by RT-qPCR AUC From Day 1 Through Day 49
    End point description
    Six participants (3 in each treatment group) had detectable RSV by RT-qPCR at baseline and were included in the mITT by RT-qPCR analysis population. The placebo-treated participant with the adjudicated LRTC had high viral load (>8 log10 copies/mL) at all post-treatment timepoints. All other participants achieved RSV viral load at or below the limit of detection. RSV viral load showed a -7 log10 copies/mL change from baseline in the EDP-938 treatment arm compared to a -2 log10 copies/mL change in the placebo arm on Day 49. In the mITT population, the mean (SD) RSV RNA viral load AUC was 109.9 (43.4) days × log10 copies/mL in the EDP-938 group vs. 232.5 (189.3) days × log10 copies/mL in the placebo group.
    End point type
    Secondary
    End point timeframe
    From Day 1 through Day 49
    End point values
    EDP-938 Placebo
    Number of subjects analysed
    3
    3
    Units: number
    arithmetic mean (standard deviation)
        RSV Viral Load by RT-qPCR AUC from Day 1 - Day 49
    109.904 ( 43.4419 )
    232.480 ( 189.2527 )
    No statistical analyses for this end point

    Secondary: RSV Viral Load by CBIA by Days 1, 4, 7, 11, 16, 21, 28, and 49

    Close Top of page
    End point title
    RSV Viral Load by CBIA by Days 1, 4, 7, 11, 16, 21, 28, and 49
    End point description
    Two participants (1 in each treatment group) had detectable RSV by CBIA at baseline and were included in the mITT by CBIA analysis population. Given this limited sample size, detailed comparisons of the treatment groups were not performed. The RSV by CBIA assessments in these 2 individuals are provided below: • The EDP-938 treated participant had RSV viral load measurements of 4.3 log10 TCID50/mL on Day 1, 3.6 log10 TCID50/mL on Day 4, and target not detected on Days 7, 11, 16, 21, 28, and 49. • The placebo-treated participant had RSV viral load measurements of 5.7 log10 TCID50/mL on Day 1 and target not detected on Days 4, 7, 11, 16, 21, 28, and 49
    End point type
    Secondary
    End point timeframe
    From Day 1 through Day 49
    End point values
    EDP-938 Placebo
    Number of subjects analysed
    1
    1
    Units: number
    number (not applicable)
        log10 TCID50/mL - Day 1
    4.3
    5.7
        log10 TCID50/mL - Day 4
    3.6
    0
        log10 TCID50/mL on Days 7, 11, 16, 21, 28 and 49
    0
    0
    No statistical analyses for this end point

    Secondary: FLU-PRO questionnaire scores through Day 49

    Close Top of page
    End point title
    FLU-PRO questionnaire scores through Day 49
    End point description
    The mean FLU-PRO total scores showed symptom improvement with a -1.2 decrease from baseline in the EDP-938 arm compared to a -0.6 decrease in the placebo arm on Day 49 in the ITT population. This mean change was based on 2 participants on each treatment group that had both baseline and Day 49 and FLU-PRO total scores. The detailed summary statistics of the FLU-PRO symptom scores on Days 1, 4, 7, 11, 16, 21, 28, and 49.
    End point type
    Secondary
    End point timeframe
    Through Day 49
    End point values
    EDP-938 Placebo
    Number of subjects analysed
    5
    4
    Units: number
    arithmetic mean (standard deviation)
        Change from Baseline - Day 4
    -0.333 ( 0.2954 )
    -0.156 ( 0.0442 )
        Change from Baseline - Day 7
    -0.177 ( 0.4161 )
    0.198 ( 0.6748 )
        Change from Baseline - Day 11
    -0.490 ( 0.3207 )
    -0.302 ( 0.1263 )
        Change from Baseline - Day 16
    -0.615 ( 0.3622 )
    -0.490 ( 0.0722 )
        Change from Baseline - Day 21
    -0.875 ( 0.5144 )
    -0.563 ( 0.1432 )
        Change from Baseline - Day 28
    -0.906 ( 0.5788 )
    -0.547 ( 0.1547 )
        Change from Baseline - Day 49
    -1.172 ( 0.1989 )
    -0.594 ( 0.1768 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    The reported adverse events are collected since the start of the study till the follow-up period completeness.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    EDP-938
    Reporting group description
    -

    Reporting group title
    Placebo
    Reporting group description
    -

    Serious adverse events
    EDP-938 Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 5 (60.00%)
    0 / 4 (0.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hypertransaminasaemia
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Mucosal infection
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    EDP-938 Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    5 / 5 (100.00%)
    3 / 4 (75.00%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Oedema peripheral
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
         occurrences all number
    0
    1
    Pain
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Pyrexia
         subjects affected / exposed
    2 / 5 (40.00%)
    0 / 4 (0.00%)
         occurrences all number
    2
    0
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Dyspnoea
         subjects affected / exposed
    2 / 5 (40.00%)
    0 / 4 (0.00%)
         occurrences all number
    2
    0
    Productive cough
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Hallucination
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Insomnia
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Nervous system disorders
    Cerebellar infarction
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Intensive care unit acquired weakness
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Blood and lymphatic system disorders
    Anaemia of chronic disease
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Febrile neutropenia
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Neutropenia
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Thrombocytopenia
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
         occurrences all number
    0
    1
    Ear and labyrinth disorders
    Middle ear inflammation
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    1 / 5 (20.00%)
    1 / 4 (25.00%)
         occurrences all number
    1
    1
    Nausea
         subjects affected / exposed
    2 / 5 (40.00%)
    1 / 4 (25.00%)
         occurrences all number
    2
    1
    Stomatitis
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Swollen tongue
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
         occurrences all number
    0
    1
    Vomiting
         subjects affected / exposed
    2 / 5 (40.00%)
    1 / 4 (25.00%)
         occurrences all number
    2
    1
    Hepatobiliary disorders
    Hypertransaminasaemia
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Skin and subcutaneous tissue disorders
    Hyperhidrosis
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
         occurrences all number
    0
    1
    Pruritus
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Rash maculo-papular
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Renal and urinary disorders
    Renal impairment
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Endocrine disorders
    Inappropriate antidiuretic hormone secretion
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
         occurrences all number
    0
    1
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Muscle spasms
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Infections and infestations
    Cellulitis
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Conjunctivitis
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
         occurrences all number
    0
    1
    Cytomegalovirus hepatitis
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Cytomegalovirus infection
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Cytomegalovirus infection reactivation
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Epstein-Barr virus infection reactivation
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Folliculitis
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
         occurrences all number
    0
    1
    Mucosal infection
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Pneumonia
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Sepsis
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Urinary tract infection
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Metabolism and nutrition disorders
    Calcium deficiency
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Decreased appetite
         subjects affected / exposed
    2 / 5 (40.00%)
    0 / 4 (0.00%)
         occurrences all number
    2
    0
    Hypervolaemia
         subjects affected / exposed
    0 / 5 (0.00%)
    1 / 4 (25.00%)
         occurrences all number
    0
    1
    Hypocalcaemia
         subjects affected / exposed
    1 / 5 (20.00%)
    1 / 4 (25.00%)
         occurrences all number
    1
    1
    Hypokalaemia
         subjects affected / exposed
    2 / 5 (40.00%)
    0 / 4 (0.00%)
         occurrences all number
    2
    0
    Hypomagnesaemia
         subjects affected / exposed
    2 / 5 (40.00%)
    0 / 4 (0.00%)
         occurrences all number
    2
    0
    Hyponatraemia
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Vitamin C deficiency
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Vitamin D deficiency
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0
    Zinc deficiency
         subjects affected / exposed
    1 / 5 (20.00%)
    0 / 4 (0.00%)
         occurrences all number
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    13 Aug 2021
    Protocol Version 4.0: 1. Changed age range of study population from 18 to 75 years to 16 to 75 years 2. Changed Sponsor Medical Officer 3. Changed protocol signatories 4. Modified a secondary endpoint and added a new secondary endpoint 5. In the pharmacokinetic (PK) secondary endpoint, added EDP-938 metabolite to list of analytes for PK analyses 6. Added dose modifications for subjects taking concomitant azole antifungal medications that are moderate or strong inhibitors of CYP3A4. 7. Changed chest X-ray to chest imaging 8. Specified time windows for HCTs 8. Changed entry criteria for oxygen saturation from >92% on room air to >95% on room air 9. Added text about treatment of HCT recipients with azole antifungals. 10. Added Study EDP 938-007 to list of EDP-938 clinical studies and added text about results of Studies 938-003 and 938-007. 11. Updated potential risk language to include information on phototoxicity 12. Clarified timing of RSV diagnosis 13. Added body weight as an inclusion criterion. 14. Changed contraceptive requirements 15. Clarified type of treatment in exclusion criterion 7 16. Clarified wording in exclusion criterion 11 17. Changed QTcF threshold in exclusion criterion 12 from >500 msec to >470 msec 18. Modified exclusion criterion and prohibited medications to allow prophylactic azole antifungal therapies 19. Added hypersensitivity to placebo or its excipients as an exclusion criterion and added a list of excipients. 20. Added definition of end of the study 21. Noted that the use of ribavirin for the treatment of RSV is allowed throughout the trial at the discretion of the Investigator 22. Removed “preliminary” from description of results of Study EDP 938-004 23. Added 150 mg tablet to drug product section. Deleted information about tablet count per bottle. 24. Added PRA Pharmacovigilance Group to unblinded list 25. Revised unblinding procedures. 26. Added other regions for 24hour safety hotline
    07 Mar 2023
    Protocol Version 8.0 1. Updated title for sponsor signatory 2. Added study stopping rules

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 18:11:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA